Anstee QM - Search Results

1

Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?

McPherson S, Anstee QM, Henderson E, Day CP, Burt AD. McPherson S, et al. Among authors: anstee qm. Eur J Gastroenterol Hepatol. 2013 Jun;25(6):652-8. doi: 10.1097/MEG.0b013e32835d72cf. Eur J Gastroenterol Hepatol. 2013. PMID: 23325287

2

The safe use of percutaneous gastrostomy for enteral nutrition in patients with Crohn's disease.

Anstee QM, Forbes A. Anstee QM, et al. Eur J Gastroenterol Hepatol. 2000 Oct;12(10):1089-93. doi: 10.1097/00042737-200012100-00004. Eur J Gastroenterol Hepatol. 2000. PMID: 11057453

3

Effect of a thrombin receptor (protease-activated receptor 1, PAR-1) gene polymorphism in chronic hepatitis C liver fibrosis.

Martinelli A, Knapp S, Anstee Q, Worku M, Tommasi A, Zucoloto S, Goldin R, Thursz M. Martinelli A, et al. J Gastroenterol Hepatol. 2008 Sep;23(9):1403-9. doi: 10.1111/j.1440-1746.2007.05220.x. Epub 2007 Nov 14. J Gastroenterol Hepatol. 2008. PMID: 18005014

4

Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis.

Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, Thomas HC, Thursz MR, Goldin RD. Anstee QM, et al. J Hepatol. 2010 Sep;53(3):542-50. doi: 10.1016/j.jhep.2010.03.016. Epub 2010 May 26. J Hepatol. 2010. PMID: 20557969

5

Genetics of alcoholic and nonalcoholic fatty liver disease.

Anstee QM, Daly AK, Day CP. Anstee QM, et al. Semin Liver Dis. 2011 May;31(2):128-46. doi: 10.1055/s-0031-1276643. Epub 2011 May 2. Semin Liver Dis. 2011. PMID: 21538280 Review.

6

The role of hypercoagulability in liver fibrogenesis.

Anstee QM, Dhar A, Thursz MR. Anstee QM, et al. Clin Res Hepatol Gastroenterol. 2011 Sep;35(8-9):526-33. doi: 10.1016/j.clinre.2011.03.011. Epub 2011 May 14. Clin Res Hepatol Gastroenterol. 2011. PMID: 21570930 Review.

7

The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.

Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK. Al-Serri A, et al. Among authors: anstee qm. J Hepatol. 2012 Feb;56(2):448-54. doi: 10.1016/j.jhep.2011.05.029. Epub 2011 Jul 12. J Hepatol. 2012. PMID: 21756849

8

How big a problem is non-alcoholic fatty liver disease?

Anstee QM, McPherson S, Day CP. Anstee QM, et al. BMJ. 2011 Jul 18;343:d3897. doi: 10.1136/bmj.d3897. BMJ. 2011. PMID: 21768191 No abstract available.

9

Genetic modifiers of non-alcoholic fatty liver disease progression.

Anstee QM, Daly AK, Day CP. Anstee QM, et al. Biochim Biophys Acta. 2011 Nov;1812(11):1557-66. doi: 10.1016/j.bbadis.2011.07.017. Epub 2011 Aug 5. Biochim Biophys Acta. 2011. PMID: 21840395 Review.

10

A lipid to treat non-alcoholic fatty liver disease - the dawn of 'lipo-rehabilitation'?

Anstee QM, Day CP. Anstee QM, et al. J Hepatol. 2012 Apr;56(4):987-9. doi: 10.1016/j.jhep.2011.10.002. Epub 2011 Oct 18. J Hepatol. 2012. PMID: 22015962

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results